217 related articles for article (PubMed ID: 33946067)
1. Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials.
Lin H; Liang G; Wu Y; Chen L
Cardiology; 2021; 146(4):469-480. PubMed ID: 33946067
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
3. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies.
Elghazawy H; Venkatesulu BP; Verma V; Pushparaji B; Monlezun DJ; Marmagkiolis K; Iliescu CA
Crit Rev Oncol Hematol; 2020 Sep; 153():103006. PubMed ID: 32777728
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials.
Fang K; Zhang Y; Liu W; He C
Heart Fail Rev; 2021 Jan; 26(1):101-109. PubMed ID: 31900787
[TBL] [Abstract][Full Text] [Related]
5. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
6. Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?-a meta-analysis of randomized controlled trials.
Dong H; Yao L; Wang M; Wang M; Li X; Sun X; Yu X; Guo J; Li X; Xu Y
Transl Cancer Res; 2020 Nov; 9(11):7034-7043. PubMed ID: 35117309
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on left ventricular mass index and ejection fraction in hemodialysis patients: A meta-analysis with trial sequential analysis of randomized controlled trials.
Yang Y; Wang R; Li MX; Xing Y; Li WG
Int J Cardiol; 2016 Sep; 219():350-7. PubMed ID: 27352206
[TBL] [Abstract][Full Text] [Related]
8. Effects of adding Rheum officinale to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal function in patients with chronic renal failure: A meta-analysis of randomized controlled trials
.
Yang Y; Ma YP; Zhang Z; Dai PL; Li P; Li WG
Clin Nephrol; 2018 Jun; 89(6):445-454. PubMed ID: 29208203
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
11. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
13. Impact of renin-angiotensin system blockade on the prognosis of acute coronary syndrome based on left ventricular ejection fraction.
Raposeiras-Roubín S; Abu-Assi E; Cespón-Fernández M; Ibáñez B; García-Ruiz JM; D'Ascenzo F; Simao Henriques JP; Saucedo J; Caneiro-Queija B; Cobas-Paz R; Muñoz-Pousa I; Wilton SB; González Juanatey JR; Kikkert WJ; Núñez-Gil I; Ariza-Solé A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Gaita F; Huczek Z; Nie SP; Yan Y; Fujii T; Correia L; Kawashiri MA; Kedev S; Southern D; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Giordana F; Kowara M; Filipiak K; Wang X; Fan JY; Ikari Y; Nakahayshi T; Sakata K; Yamagishi M; Kalpak O; Íñiguez-Romo A
Rev Esp Cardiol (Engl Ed); 2020 Feb; 73(2):114-122. PubMed ID: 31105064
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
Lakhdar R; Al-Mallah MH; Lanfear DE
J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
[TBL] [Abstract][Full Text] [Related]
15. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker therapy for IgA nephropathy: A meta-analysis of randomized controlled trials.
Ji Y; Yang K; Xiao B; Lin J; Zhao Q; Bhuva MS; Yang H
J Cell Biochem; 2019 Mar; 120(3):3689-3695. PubMed ID: 30270542
[TBL] [Abstract][Full Text] [Related]
17. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.
Ma Y; Bai F; Qin F; Li J; Liu N; Li D; Li T; Xie H; Liu D; Zhou S; Liu Q
BMC Pharmacol Toxicol; 2019 Apr; 20(1):18. PubMed ID: 31023386
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials.
Zhao YT; Li PY; Zhang JQ; Wang L; Yi Z
Medicine (Baltimore); 2016 May; 95(18):e3600. PubMed ID: 27149494
[TBL] [Abstract][Full Text] [Related]
19. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
20. The role of neurohormonal blockers in the primary prevention of acute-, early-, and late-onset anthracycline-induced cardiotoxicity.
Ayuna A; Abidin N
Egypt Heart J; 2020 Sep; 72(1):59. PubMed ID: 32915331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
